Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAI-9531 injection site bioavailability study
NCT07044401Phase 1Completed
- Sponsor
- Kailera Therapeutics
- Start
- Jul 2025
- Primary completion
- Nov 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS9531 (3 arms), sponsored by Kailera Therapeutics. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-time Curve From 0 to Time of Last Quantifiable Concentration and 1 more. Started Jul 2025; status: completed.
02
Drugs
HRS9531
Beyond the preview
Go deeper on NCT07044401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044401.